LXRX - Total Utang marang Modal Lexicon Corp

Logo perusahaan publik Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals (LXRX) is a reputable developer of treatments for cardiac pathologies and metabolic disorders, having earned physician recognition for the precision of its medications. The stock chart on GURU.Markets, where the total debt-to-equity ratio stands at 0.35, links the brand's scientific image with the creation of a comprehensive therapy system for the kidneys and heart. The company is currently scaling sales of a new product by expanding its reach among practicing cardiologists.

LXRX: Total Utang marang Modal Lexicon Pharmaceuticals, Inc. 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Lexicon Pharmaceuticals

- rega lan prakiraan konsensus rega:
Bagan rega Lexicon Pharmaceuticals, Inc.|LXRX - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Lexicon Pharmaceuticals|LXRX - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Lexicon Pharmaceuticals|LXRX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku lexpharma.com|LXRX - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Lexicon Pharmaceuticals|LXRX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Lexicon Pharmaceuticals|LXRX - Gunggung utang perusahaan|Utang marang nilai buku Lexicon Pharmaceuticals|LXRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lexicon Pharmaceuticals|Rasio cepet lexpharma.com
- informasi bathi lan kelipatan valuasi:
LXRX - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Lexicon Pharmaceuticals, Inc.
Barang utama Lexicon Corp

Investors must find a balance between operational risks and return on invested capital. Lexicon Pharmaceuticals (LXRX) focuses on expansion within the cardiovascular and metabolic disease therapy segment. The debt-to-equity ratio trend reflects the proportion of total liabilities relative to the organization's net assets. An increase in this ratio signals higher leverage in financing new developments, while low values confirm strong financial autonomy and business resilience.

Analisis pesaing Lexicon Pharmaceuticals

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|MBX Biosciences Inc - Total Utang marang Modal|Utang marang Modal altimmune.com|AARD (Aardvark Therapeutics) - Rasio Total Utang marang Ekuitas|SGMT: Utang Agregat marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|radiuspharm.com - Utang marang Ekuitas